![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » FDA Grants Orphan Drug Status to Eisai’s Investigational Compound for Cutaneous T-Cell Lymphoma
FDA Grants Orphan Drug Status to Eisai’s Investigational Compound for Cutaneous T-Cell Lymphoma
August 8, 2013
The FDA has granted orphan drug designation to Eisai’s investigational drug E777 for the rare cutaneous t-cell lymphoma. E777 is currently being evaluated in a clinical trial that will determine its eligibility for further FDA approval.
Yahoo! Finance
Yahoo! Finance
Upcoming Events
-
21Oct